What every peptide story means for the people actually using these compounds — access, cost, availability, and the real-world impact behind the headlines.
This article offers a patient perspective on the recent FDA approval of Cobenfy, the first new antipsychotic drug in decades. While acknowledging the drug's potential to reduce debilitating side effects like weight gain and movement disorders, the author expresses hesitation to try it due to a deep-seated lack of trust in the mental health care system and pharmaceutical companies. The piece highlights that medication non-adherence is often driven by systemic trauma and mistrust, not just side effects.
The FDA's standing consumer-safety statement on unapproved GLP-1 weight-loss drugs — updated in mid-2026 — reports 990 adverse events tied to compounded semaglutide and over 730 tied to compounded tirzepatide as of May 31, 2026, including dosing errors that required hospitalization. The agency reiterates that retatrutide and cagrilintide cannot lawfully be compounded at all, warns that products falsely labeled "for research purposes" are being sold directly to consumers with dosing instructions, and has posted an import alert (66-80) to block suspect foreign-made active ingredients. The warning coincides with a broader 2025–2026 enforcement arc: dozens of warning letters to telehealth marketers and, per trade reporting, explicit FDA threats of seizure and injunction.
Cardiologist Eric Topol takes a critical look at the peptide boom, noting that beyond GLP-1 receptor agonists — which have robust outcome data — most other peptides in the wellness market still lack proven health-outcome benefits. A useful framing for separating the evidence-backed class from the hype.
A November 2025 New York Times explainer takes a skeptical consumer lens to the peptide-therapy craze, separating the few uses with reasonable evidence (topical GHK-Cu and Matrixyl-type peptides in skincare) from the largely unproven injectable and "biohacking" market (BPC-157, TB-500, epitalon, semax, selank). Dermatologists frame cosmetic peptides as "sidekicks, not hero ingredients," while endocrinologists warn that growth-hormone-releasing peptides like sermorelin and tesamorelin carry the same long-term risks as HGH — diabetes, certain cancers, and acromegaly. The piece notes that most longevity claims rest on cell-culture or animal data only, and that "research-grade" products have no quality controls.
A November 2025 CNN report documents how celebrities and wellness influencers are fueling mass consumer use of unapproved peptides like BPC-157, TB-500, ipamorelin, and CJC-1295, many sold with a "for research use only" label that lawyers and regulators describe as a loophole to evade FDA oversight. Health Secretary Robert F. Kennedy Jr. has vowed to end the agency's "war on peptides," while named sellers such as biohacker Gary Brecka market injectable vials for $350 to $600 each. Independent experts — including Scripps' Dr. Eric Topol and UC Davis biologist Paul Knoepfler — stress that none of these compounds have passed adequate clinical trials and that "research-grade" powders often contain contaminants. BPC-157 and TB-500 are also banned by international sports authorities as doping substances.
A June 2025 Reuters investigation details a fast-growing "gray market" in which Americans import bulk semaglutide, tirzepatide, retatrutide, and cagrilintide powders from Chinese vendors — labeled as research materials — and reconstitute them into injectable weight-loss drugs at home for roughly one-tenth of the brand-name price. Buyers coordinate on Reddit and Telegram (one group, StairwayToGray, surpassed 21,000 members), pooling money for third-party purity testing. Eli Lilly and Novo Nordisk call the practice dangerous and illicit, and 38 state attorneys general asked the FDA to intervene. One profiled user overdosed after a self-dosing miscalculation, highlighting the absence of medical oversight.